Femasys Inc (FEMY): R&D Expense

Annual figures by period end, from SEC filings.

$7.58M
Year ended 2025-12-31
$6.45M
Trailing 12 months to 2026-06-30
+9.2%
3-year compound annual growth
+12.9%
5-year compound annual growth
$8.22M2020-12-31: $4.13M2021-12-31: $4.08M2022-12-31: $5.81M2023-12-31: $7.21M2024-12-31: $8.22M2025-12-31: $7.58M$7.58M
2020-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$7.58M-7.8%2026-03-31, From 2025-01-01
2024-12-31$8.22M+14.0%2026-03-31, From 2024-01-01
2023-12-31$7.21M+24.0%2025-03-27, From 2023-01-01
2022-12-31$5.81M+42.3%2024-03-28, From 2022-01-01
2021-12-31$4.08M-1.1%2023-07-24, From 2021-01-01
2020-12-31$4.13Mn/a2022-03-24, From 2020-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Femasys Inc (FEMY)2025-12-31$7.58M-7.8%
QHSLab, Inc. (USAQ)2025-12-31$484.9K+64.7%
Vycor Medical Inc (VYCO)2025-12-31$10.0K-35.0%
OSR Health, Inc. (OSRH)2025-12-31$318.4K+97.6%
EBR Systems, Inc. (NONE.)2025-12-31$23.94M-11.5%
IceCure Medical Ltd. (ICCM)2025-12-31$7.43M+4.7%
Tenon Medical, Inc. (TNON)2025-12-31$2.15M-17.4%
SeaStar Medical Holding Corp (ICU)2025-12-31$7.52M-17.4%
PetVivo Holdings, Inc. (PETV)2026-03-31$1.42M-10.6%

Compare FEMY, USAQ, VYCO, OSRH side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗